Lilly reports Phase 3b EBGLYSS data
Lilly said new Phase 3b data for EBGLYSS showed significant and rapid improvements in skin clearance, itch, pain and patient satisfaction in moderate-to-severe hand and foot atopic dermatitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.